Arthritis, autoimmune disease discovery could lead to new treatments

November 21, 2017 by Lisa Marshall, University of Colorado at Boulder
Hubert Yin in his lab at the BioFrontiers Institute. Credit: Glenn Asakawa/CU Boulder

More than 23.5 million Americans suffer from autoimmune diseases like rheumatoid arthritis, scleroderma and lupus, in which an overzealous immune response leads to pain, inflammation, skin disorders and other chronic health problems. The conditions are so common that three of the top five selling drugs in the United States aim to ease their symptoms. But no cure exists, and treatments are expensive and come with side effects.

Now CU Boulder researchers have developed a potent, drug-like compound that could someday revolutionize treatment of such diseases by inhibiting a protein instrumental in prompting the body to start attacking its own tissue.

"We have discovered a key to lock this protein in a resting state," said Hang Hubert Yin, a biochemistry professor in the BioFrontiers Institute and lead author of a paper, published today in Nature Chemical Biology, describing the discovery. "This could be paradigm shifting."

For years, scientists have suspected that a protein called Toll-like receptor 8 (TLR8) plays a key role in the . When it senses the presence of a virus or bacteria, it goes through a series of steps to transform from its passive to , triggering a cascade of inflammatory signals to fight off the foreign invader. But, as Yin explained, "it can be a double-edged sword" leading to disease when that response is excessive.

Because TLR8 has a unique molecular structure and is hidden inside the endosome—an infinitesimal bubble inside the cell—rather than on the cell's surface, it has proven an extremely difficult target for drug development.

"This is a long-sought-after target with very little success," Yin said.

But his study shows a drug-like molecule called CU-CPT8m binds to and inhibits TLR8 and exerts "potent anti-inflammatory effects" on the tissue of patients with arthritis, osteoarthritis and Still's , a rare autoimmune illness.

For the study, Yin and his co-authors used high-throughput screening to look through more than 14,000 small molecule compounds to determine whether they had the right chemical structure to bind to TLR8. They identified four that shared a similar structure. Using that structure as a model, they chemically synthesized hundreds of novel compounds in an effort to find one that perfectly bound to and inhibited TLR8.

Previous efforts to target the protein have focused on shutting it down when it is in its active state. But the compound Yin developed prevents it from activating while still in its passive state.

"Before, people were trying to close the open door to shut it down. We found the key to lock the door from the inside so it never opens," Yin said.

Much more research is necessary, but that could lead to treatments that strike at the root cause of , rather than just treating symptoms. With help from CU's Technology Transfer Office, Yin has already filed a patent application and hopes to move on to animal studies and clinical trials within the next two years.

"Given the prevalence of these diseases, there is a big push for alternatives," Yin said.

In the meantime, the new compound can serve as a first-of-its kind tool to understand exactly what TLR8 and the other nine toll-like receptors do in the body.

"Our study provides the first small molecule tool to shut this protein down so we can understand its pathogenesis," Yin said.

Explore further: Lab tests show molecule appears to spur cell death in tumors, inflammation

More information: Shuting Zhang et al. Small-molecule inhibition of TLR8 through stabilization of its resting state, Nature Chemical Biology (2017). DOI: 10.1038/nchembio.2518

Related Stories

A switch for autoimmunity

October 13, 2017

When a virus or bacteria comes calling, protein "sensors" in your cells can detect the invader's DNA and activate inflammatory responses to prevent infection. One such sensor is cGAS (cyclic GMP-AMP synthase).

Recommended for you

Cellular clean-up crews linked to how body handles sugar

October 17, 2018

How our bodies handle glucose—the simple sugar that provides energy from the food we eat—appears to be intertwined with how cells keep themselves functioning normally, according to new University of Chicago research.

Chemists test a new nanocatalyst for obtaining hydrogen

October 17, 2018

A chemist from RUDN was the first to use catalysts with ruthenium nanoparticles to obtain hydrogen under the influence of visible light and UV radiation. In the future, such catalysts may be used for large-scale production ...

4 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

sirdumpalot
not rated yet Nov 21, 2017
or, https://www.ncbi....4034215/ for controlling your own immune response, dealing with inflammatory conditions by breathing exercises (yes, sounds quack, but the man has peer reviews!)
TheGhostofOtto1923
not rated yet Nov 21, 2017
or, https://www.ncbi....4034215/ for controlling your own immune response, dealing with inflammatory conditions by breathing exercises (yes, sounds quack, but the man has peer reviews!)
Yes 9 of 10 quackologists concur-
sirdumpalot
not rated yet Nov 21, 2017
And yet you'd think being able to consciously (through a slow training process) limit the reaction to E. Coli endotoxin is quite a thing! (I did a course with him.. meeting three people who had rheumatoid before they met him and now don't, is certainly not a well designed experiment/observation, but it was certainly interesting.. If you're really hungover one day, hyperventilate for 5 2 minute stretches, it's quite effective! :) )
Whydening Gyre
not rated yet Nov 21, 2017
or, https://www.ncbi....4034215/ for controlling your own immune response, dealing with inflammatory conditions by breathing exercises (yes, sounds quack, but the man has peer reviews!)

I take a hot shower and then lots of Gold Bond Excema Relief creme..
Works great...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.